Repository logo

Browsing by Issue Date, starting with "2024-11-08"

Filter results by year or month
Now showing 1 - 3 of 3
  • Observatório Nacional de Saúde: coletânea do Boletim Observações (1998-2009)
    Publication . Departamento de Epidemiologia
    Coletânea do Boletim Observações editado entre 1998-2009 pelo Observatório Nacional de Saúde fundado pelo Dr. Marinho Falcão, atual Departamento de Epidemiologia do INSA.
    2024-11-08Book Open access Show more
  • Infeção por VIH em Portugal – 2024
    Publication . Direção-Geral da Saúde, Instituto Nacional de Saúde Doutor Ricardo Jorge
    Relatório anual sobre a evolução da infeção VIH em Portugal – 2024. Este relatório conjunto DGS/ INSA apresenta os dados mais recentes da vigilância epidemiológica da infeção por VIH em Portugal, bem como resultantes de iniciativas de prevenção e rastreio desenvolvidas no âmbito do Programa Nacional para as Infeções Sexualmente Transmissíveis e Infeção pelo VIH (PNISTVIH). O relatório disponibiliza, pela primeira vez, dados sobre a Profilaxia Pós-Exposição ao VIH (PPE).
    2024-11-08Report Open access Show more
  • MicroRNAs as potential biomarkers of response to modified Atkins diet in treatment of adults with drug-resistant epilepsy: A proof-of-concept study
    Publication . Samões, Raquel; Cavalheiro, Ana; Santos, Cristina; Lopes, Joana; Teixeira, Catarina; Tavares, Maria Manuel; Carvalho, Cláudia; Lemos, Carolina; Costa, Paulo Pinho e; Cavaco, Sara; Chaves, João; Leal, Bárbara
    Background: Accurate predictors of response to modified Atkins diet (MAD) are needed. MicroRNAs are potential biomarkers in epilepsy. This study aimed to explore the value of circulating miR-146a, miR-155, miR-22, miR-21 and miR-134 levels in predicting response to MAD. Methods: Patients who completed 3 months of MAD were selected from a prospective cohort of adults with DRE followed in a specialized MAD outpatient clinic. Patients were classified as responders if any reduction in seizure frequency at follow-up, calculated through seizure-calendars). The >50 % seizure reduction cut-off was also explored. Qualitative benefits in seizures and cognition were analysed. Blood samples were collected prior to initiate MAD and microRNAs were quantified by qRT-PCR. Results: Thirty-nine patients were included (56 %males, mean age=33.1±8.5yo, 62 %focal epilepsies, 59 %structural aetiology): 20(51 %) were responders [mean reduction in seizure frequency=54 %(17-100 %); 10 had ≥50 % reduction]; 25(64 %) reported qualitative benefit in seizures and 21(54 %) reported cognitive benefits. At pre-treatment baseline, a panel combining serum levels of all studied microRNAs predicted seizure reduction (AUC=0.839, p<0.0001), qualitative benefit in seizures (AUC=0.683, p=0.048) and in cognition (AUC=0.751, p<0.01) at 3months. miR-146a was the only significant microRNA when evaluated in isolation. There was no statistical correlation in the biomarkers when a ≥50 % seizure reduction was compared to <50 %. Conclusions: A panel combining pre-treatment serum levels of miR-146a, miR-155, miR-134, miR-21 and miR-22 predicted any reduction in seizures with MAD in adults with DRE at 3months. This panel may be a promising biomarker and a useful tool in the selection of patients.
    2024-11-08Journal article Restricted access Show more